CN114829365A - 作为erk抑制剂的噻唑并内酰胺类化合物及其应用 - Google Patents

作为erk抑制剂的噻唑并内酰胺类化合物及其应用 Download PDF

Info

Publication number
CN114829365A
CN114829365A CN202080084536.XA CN202080084536A CN114829365A CN 114829365 A CN114829365 A CN 114829365A CN 202080084536 A CN202080084536 A CN 202080084536A CN 114829365 A CN114829365 A CN 114829365A
Authority
CN
China
Prior art keywords
reaction
pharmaceutically acceptable
acceptable salt
optionally substituted
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080084536.XA
Other languages
English (en)
Other versions
CN114829365B (zh
Inventor
李翼
刘宁
于涛
吴成德
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deshengji Pharmaceutical Wuxi Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN114829365A publication Critical patent/CN114829365A/zh
Application granted granted Critical
Publication of CN114829365B publication Critical patent/CN114829365B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

提供了一类噻唑并内酰胺类化合物，及其在制备治疗ERK相关疾病的药物中的应用。具体提供了式(III)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN202080084536.XA 2019-12-06 2020-12-07 作为erk抑制剂的噻唑并内酰胺类化合物及其应用 Active CN114829365B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN201911244773 2019-12-06
CN2019112447733 2019-12-06
CN2019112579906 2019-12-10
CN201911257990 2019-12-10
CN202010107001 2020-02-20
CN2020101070011 2020-02-20
CN2020111385268 2020-10-22
CN202011138526 2020-10-22
CN202011402966 2020-12-02
CN202011402966X 2020-12-02
PCT/CN2020/134286 WO2021110169A1 (zh) 2019-12-06 2020-12-07 作为erk抑制剂的噻唑并内酰胺类化合物及其应用

Publications (2)

Publication Number Publication Date
CN114829365A true CN114829365A (zh) 2022-07-29
CN114829365B CN114829365B (zh) 2023-04-25

Family

ID=76221475

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080084536.XA Active CN114829365B (zh) 2019-12-06 2020-12-07 作为erk抑制剂的噻唑并内酰胺类化合物及其应用

Country Status (9)

Country Link
US (1) US20230072937A1 (zh)
EP (1) EP4071155A4 (zh)
JP (1) JP7409719B2 (zh)
KR (1) KR20220107249A (zh)
CN (1) CN114829365B (zh)
AU (1) AU2020398022B2 (zh)
CA (1) CA3160903A1 (zh)
TW (1) TWI758999B (zh)
WO (1) WO2021110169A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022253186A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 一种二甲基取代的噻唑并吡咯酮类化合物的晶型及其制备方法
IL309706A (en) * 2021-06-28 2024-02-01 D3 Bio Wuxi Co Ltd Dimethyl-converted thiazololactam compound and its uses
IL309711A (en) * 2021-06-28 2024-02-01 D3 Bio Wuxi Co Ltd THIAZOLE-LACTAM-SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349983A (zh) * 2015-11-09 2018-07-31 阿斯利康(瑞典)有限公司 治疗癌症有用的二氢咪唑并吡嗪酮衍生物
CN109608444A (zh) * 2018-11-27 2019-04-12 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
WO2019223632A1 (en) * 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
WO2019233457A1 (zh) * 2018-06-08 2019-12-12 贝达药业股份有限公司 Erk抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611798B1 (en) * 2010-09-01 2015-04-08 Gilead Connecticut, Inc. Pyridazinones, method of making, and method of use thereof
AU2016341520C1 (en) * 2015-10-21 2021-07-22 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2020073862A1 (zh) 2018-10-10 2020-04-16 深圳市塔吉瑞生物医药有限公司 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
BR112021018924A2 (pt) * 2019-03-29 2022-02-01 Jiangsu Hengrui Medicine Co Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
CN110950876B (zh) * 2019-12-10 2021-08-17 上海凌达生物医药有限公司 一类呋喃并内酰胺类化合物、制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349983A (zh) * 2015-11-09 2018-07-31 阿斯利康(瑞典)有限公司 治疗癌症有用的二氢咪唑并吡嗪酮衍生物
WO2019223632A1 (en) * 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
WO2019233457A1 (zh) * 2018-06-08 2019-12-12 贝达药业股份有限公司 Erk抑制剂及其应用
CN109608444A (zh) * 2018-11-27 2019-04-12 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途

Also Published As

Publication number Publication date
TWI758999B (zh) 2022-03-21
CN114829365B (zh) 2023-04-25
US20230072937A1 (en) 2023-03-09
TW202128710A (zh) 2021-08-01
EP4071155A4 (en) 2024-01-17
KR20220107249A (ko) 2022-08-02
AU2020398022A1 (en) 2022-07-14
EP4071155A1 (en) 2022-10-12
AU2020398022B2 (en) 2023-04-27
JP7409719B2 (ja) 2024-01-09
WO2021110169A1 (zh) 2021-06-10
CA3160903A1 (en) 2021-06-10
JP2023505288A (ja) 2023-02-08

Similar Documents

Publication Publication Date Title
CN114829365A (zh) 作为erk抑制剂的噻唑并内酰胺类化合物及其应用
CN113784970B (zh) Erk抑制剂及其应用
WO2021110168A1 (zh) 作为erk抑制剂的螺环类化合物及其应用
WO2022166890A1 (zh) 取代的哒嗪苯酚类衍生物
US20230348441A1 (en) Bicyclic compound that acts as crbn protein regulator
CN112672994A (zh) 作为lsd1抑制剂的杂螺环类化合物及其应用
WO2023036175A1 (zh) 戊二酰亚胺类化合物与其应用
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
CN114761407A (zh) 作为高选择性ros1抑制剂的化合物及其应用
WO2019201296A1 (zh) 作为rho激酶抑制剂的吡唑类化合物
WO2020156564A1 (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
RU2805569C1 (ru) Тиазололактамные соединения в качестве ингибиторов ERK и их применение
TWI839945B (zh) 吡唑並環化合物及其應用
WO2023083200A1 (zh) 吡唑并环化合物及其应用
CN114945576B (zh) 氘代噻吩并吡啶类化合物
TWI825811B (zh) 噻唑並內醯胺並螺雜環類化合物及其應用
WO2023274088A1 (zh) 二甲基取代的噻唑并内酰胺类化合物及其应用
CN113801120B (zh) Mdm2抑制剂的微悬浮液以及治疗应用
CN114957259A (zh) 氰基取代的芳香双环类化合物及其应用
US20220204507A1 (en) Nitrogen-containing spiro derivative as ret inhibitor
US20240109879A1 (en) Benzimidazole compound and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069880

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230925

Address after: 324, No. 88, Meiliang Road, Mashan Street, Binhu District, Wuxi City, Jiangsu Province, 214092

Patentee after: Deshengji Pharmaceutical (Wuxi) Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.

TR01 Transfer of patent right